VERQUVO

Peak

vericiguat

NDAORALTABLETPriority Review
Approved
Jan 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Guanylate Cyclase Stimulators

Pharmacologic Class:

Soluble Guanylate Cyclase Stimulator

Clinical Trials (5)

NCT06632483N/AActive Not Recruiting

An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

Started Sep 2025
1,200 enrolled
Chronic Heart Failure With Reduced Ejection FractionWorsening Chronic Heart Failure
NCT06415227Phase 2Not Yet Recruiting

The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris

Started Apr 2025
55 enrolled
Vasospastic Angina
NCT06697353N/ACompleted

An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

Started Nov 2024
4,936 enrolled
Chronic Heart FailureChronic Heart Failure With Reduced Ejection Fraction
NCT06486844N/ACompleted

An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany

Started Jul 2024
500 enrolled
Chronic Heart Failure With Reduced Ejection Fraction
NCT06474208Phase 1Completed

A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years

Started Jul 2024
19 enrolled
Heart Failure

Loss of Exclusivity

LOE Date
Nov 26, 2032
81 months away
Patent Expiry
Nov 26, 2032
Exclusivity Expiry
Jan 21, 2029

Patent Records (5)

Patent #ExpiryTypeUse Code
10736896
May 19, 2031
SubstanceProduct
11439642
May 19, 2031
U-3062
8420656
May 19, 2031
SubstanceProduct
8921377
May 19, 2031
U-3062
9993476
May 19, 2031
U-3062